^
Association details:
Biomarker:FABP7 overexpression
Cancer:Glioma
Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma

Published date:
06/24/2022
Excerpt:
FABP7 was highly expressed in glioma samples, with higher FABP7 expression associated with poorer patient prognosis and more advanced clinicopathological features….Immunohistochemistry showed that FABP7 expression was higher in glioma patients with poor survival after apatinib treatment....The results indicated that FABP7 was more highly expressed in patients with shorter than longer OS (Figures 7(a)–7(c))....The present study found that high expression of FABP7 correlated with poor prognosis in patients with glioma.
DOI:
10.1155/2022/2091791